Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias F Seidel

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Rheumatology International|March 28, 2008
Serotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cellsMatthias F Seidel, Bernd L Fiebich, Gudrun Ulrich-Merzenich, et al.
Orphanet Journal of Rare Diseases|November 1, 2020
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysisTim T A Bender, Judith Leyens, Julia Sellin, et al.
Orphanet Journal of Rare Diseases|July 23, 2021
The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitisJudith Leyens, Tim Th A Bender, Martin Mücke, et al.
Experimental Neurology|May 13, 2022
Neurogenic inflammation as a novel treatment target for chronic pain syndromesMatthias F Seidel, Thomas Hügle, Barton Morlion, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi techniqueJoerg H W Distler, Suzana Jordan, Paolo Airo, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Rheumatology International|March 28, 2008
Serotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cellsMatthias F Seidel, Bernd L Fiebich, Gudrun Ulrich-Merzenich, et al.
Orphanet Journal of Rare Diseases|November 1, 2020
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysisTim T A Bender, Judith Leyens, Julia Sellin, et al.
Orphanet Journal of Rare Diseases|July 23, 2021
The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitisJudith Leyens, Tim Th A Bender, Martin Mücke, et al.
Experimental Neurology|May 13, 2022
Neurogenic inflammation as a novel treatment target for chronic pain syndromesMatthias F Seidel, Thomas Hügle, Barton Morlion, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi techniqueJoerg H W Distler, Suzana Jordan, Paolo Airo, et al.
Pageof 2